BRD9 and adrenal cortex carcinoma: We also compared BRD9 mRNA expression between tumors and their corresponding control specimens from TCGA, except ACC, OV, and CESC, for which the RNA-seq profile from a normal control is unavailable (ACC and OV) or insufficient for sample numbers (CESC, n = 3) at TCGA.